Ad hoc announcement pursuant to Art. 53 LR 2025/08/07
Galenica demonstrates pleasing growth and improves EBIT guidance
- Galenica Group sales grew by 5.0% to CHF 1,995.4 million in the first half of 2025.
- Adjusted EBIT1 increased by 10.9% to CHF 109.9 million – supported by positive one-time effects of CHF 5.4 million.
- Galenica is therefore raising its EBIT guidance and now expects growth between 7% and 9% (previously growth between 4% and 6%).
- Guidance for 2025 sales growth remains unchanged at 3% to 5%, the dividend is expected to remain at least at the previous year’s level.
Galenica recorded pleasing growth in a positive market environment in the first half of 2025. Both the “Products & Care” segment (+4.6%) and the “Logistics & IT” segment (+5.5%) contributed to the increase in sales of 5.0% to CHF 1,995.4 million. As a result, Galenica Group sales grew slightly stronger than the pharmaceutical market (+4.8%2) and the consumer healthcare market (+0.6%3).
Strong sales growth in prescription drugs
Following an increase of 4.7% by the end of April 2025, Galenica Group sales increased further in May and June 2025. Growth in the first half of the year was driven by strong demand for prescription drugs, including GLP-1-based4 weight loss products, as well as drugs associated with the heavy flu season early in the year. The good result was achieved despite one less day of sales compared to the same period in the previous year.
Reported EBIT increased by 6.2% to CHF 108.8 million, while adjusted EBIT1 increased by 10.9% to CHF 109.9 million. In the first half of 2025, EBIT was supported by the pleasing sales growth as well as by positive one-off effects in the amount of CHF 5.4 million. Without these effects, adjusted EBIT1 would have increased by 5.4%. The reason for this is that fines in two competition proceedings were significantly lower than originally expected, positively impacting the “Logistics & IT” segment.
Improved EBIT guidance for the second half of the year
Galenica confirms its 2025 outlook for consolidated net sales with growth of between 3% and 5% and the dividend at least at the same level as the previous year. Due to the strong growth in the first half of the year and positive one-time effects of CHF 5.4 million, Galenica now expects an EBIT1 increase of between 7% and 9%. Prior to this, growth of between 4% and 6% had been expected.
In early July 2025, Galenica announced the acquisition of the diagnostics service provider Labor Team. As the closing date of the transaction has not yet been determined, the Labor Team Group is not yet included in the 2025 guidance.
Key figures of the Galenica Group in the first half of 2025
(in million CHF) | 1st half of 2025 | 1st half of 2024 | Change |
|---|---|---|---|
Net sales | |||
Products & Care segment | 867.3 | 829.3 | +4.6% |
Retail (B2C) | 731.1 | 695.4 | +5.1% |
Local Pharmacies | 693.1 | 657.6 | +5.4% |
Pharmacies at Home | 38.1 | 37.9 | +0.3% |
Professionals (B2B) | 140.9 | 138.4 | +1.8% |
Products & Brands | 97.8 | 97.0 | +0.9% |
Services for Professionals | 43.1 | 41.4 | +4.0% |
Logistics & IT segment | 1,649.7 | 1,563.3 | +5.5% |
Wholesale | 1,579.6 | 1,496.5 | +5.6% |
Logistics & IT Services | 83.0 | 77.7 | +6.9% |
Corporate and eliminations | -521.7 | -492.6 | |
Galenica Group | 1,995.4 | 1,900.0 | +5.0% |
EBIT adjusted1 | |||
Products & Care segment | 79.5 | 75.9 | +4.6% |
Logistics & IT segment | 32.0 | 25.4 | +25.8% |
Corporate and eliminations | -1.6 | -2.2 | |
Galenica Group | 109.9 | 99.1 | +10.9% |
Net profit from ongoing business activities adjusted1 | 90.7 | 77.7 | +16.8% |
1) Excluding the effects of IFRS 16 and IAS 19 (details of the adjusted key figures in the half year report 2025)
2) IQVIA, Pharmaceutical Market Switzerland, YTD June 2025.
3) IQVIA, Consumer Health Market Switzerland, YTD June 2025.
4) GLP-1 stands for glucagon-like peptide 1, a hormone produced in the intestine and which plays an important role in regulating blood sugar levels.
Detailed information in the half year report 2025:
- Management report of the Galenica Group
- Management report for the Products & Care segment
- Management report for the Logistics & IT segment
- Key figures
Conference call at 2 p.m. Galenica will host a Zoom Conference Call on the results for the first half of 2025 today, Thursday, 7 August 2025, at 2 p.m. (CEST). You can follow the Zoom conference via this link: Zoom conference (meeting: 880 3349 4358, code: 2466) The conference will be held in German with simultaneous English interpreting. The presentation will be available on the website from around 12 noon (CEST) on 7 August 2025. A recording of the conference call will then be made available on the website. |
You might also be interested in this
New internal appointment of General Counsel and Secretary General
Barbara Wälchli, General Counsel and Secretary General, has decided to leave Galenica at the end of 2025. With Cécile Matter as the new General Counsel and Jürg Pauli as the future Secretary General of the Board of Directors, two experienced executives from within the company are taking over the reins.
Galenica and the invisible work behind safe medications
What does it take to ensure that only safe and effective medications reach people in Switzerland? Galenica ensures that quality standards are met – from the place of manufacture all the way to the pharmacy or hospital. In this story, you’ll find out exactly how this works and what it has to do with underfloor heating.
Yves Platel is the new President of the Association of Pharmacists of the Canton of Zurich
A pharmacist from the Galenica network assumes responsibility at association level: Yves Platel, Co-Managing Director of the Amavita pharmacy at Zurich Railway Station, was elected President of the Association of Pharmacists of Zurich (AKVZ) on 19 June 2025.
Committed together – how we support social projects
Twice a year, our employees have the opportunity to cast their vote and determine the proportion of donations for social projects on the crowddonating platform “there for you”. The first round of voting in 2025 was recently completed. With our support, one of the projects directly reached the donation target.
Between conveyor belts and barcode scanners: a self-experiment in the logistics centre
What happens when an office worker dives into the world of logistics? A communications employee put it to the test and spent an evening in the Galexis logistics centre, surrounded by buzzing forklifts and countless blue boxes.
